Celldex Therapeutics Inc. (Nasdaq: CLDX) will collaborate with Bristol-Myers Squibb Co. (NYSE: BMY) to conduct a clinical trial to evaluate the effectiveness of combining nivolumab and varlilumab in treating cancer. Shares of Celldex soared $3.48 to $15.88 while Bristol-Myers stock eased 2 cents to $52.17.
Celldex Collaborates With Bristol-Myers
May 14, 2014 at 06:02 AM EDT